



# Lebanese Epi-Monitor

Updates & Reviews

Volume 7, Issue 05 — January 2019

## Current Health Event

### Cutaneous Leishmaniasis

Cutaneous Leishmaniasis (CL), a neglected tropical disease (NTD), is an important public health disease in the eastern Mediterranean region, which bears the brunt of the worldwide prevalence (470%). Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of infected female phlebotomine sandflies.

#### Editorial notes:


Leishmaniasis is mainly associated with poverty, malnutrition, population displacement, poor housing, a weak income system and lack of financial resources. The disease is linked to environmental and climate changes.

Cutaneous leishmaniasis is typically characterized by one or more cutaneous lesions that will eventually ulcerate and crust over. In severe cases, the disease is disfiguring and incapacitating and can potentially lead to life-threatening complications.

The global incidence of leishmaniasis is estimated at 700 000 to 1 million new cases with 20 000 to 30 000 deaths annually. Leishmaniasis is endemic to 16 of the 23 countries in the EMRO. Aleppo is one of the most CL-endemic areas in the world. Antroponotic cutaneous leishmaniasis, where humans are the major reservoir of the parasite, is predominantly urban and periurban, and shows patterns of spatial clustering. The disease is usually characterized by large outbreaks in densely populated cities, especially in war and conflict zones, refugee camps and in settings where there is large-scale migration of populations (WHO).

With the advent of the Syrian crisis, and the continuous influx of the Syrian and other refugees in Lebanon, an increase in leishmaniasis was documented among Syrian refugees within the Lebanese borders with 1,033 reported

Figure 1: Number of leishmaniasis cases seeking treatment in Lebanon 2002-2018 (MoPH)



leishmaniasis cases in 2013. 998 cases (96.6%) were identified among Syrian refugees and the remaining cases (3.4%) involved both Lebanese nationals and Palestinian refugees with history of travel to endemic areas in Syria (Alawieh et al., 2014).

Despite the decline in number of new Syrian refugees since 2015, Lebanon still reported treatment of around 50-300 cases of CL yearly between 2016 and 2018, mostly among Syrians displaced in Lebanon, all of them giving history of recent visit to endemic areas in Syria. This is still considered an alarming number given that before the Syrian Crisis, Lebanon was not endemic for CL and the few cases reported per year (3-6 cases yearly) were all acquired from travel to Syria.

In view of the increased risk for local transmission of CL, WHO is working closely with the MoPH to maintain the leishmania centers, to enhance detection and treatment, ensure provision of detection kits and free access to medication. WHO is also planning to conduct a vector mapping survey to assess risks of local transmission of cutaneous leishmaniasis. The preventive measures and precautions implemented by the MoPH in Lebanon have succeeded in preventing leishmania outbreaks among the Lebanese population residing in Lebanon.

The World Health Assembly (WHA) adopted a resolution on control of leishmaniasis in 2007, and in May 2011, the WHA resolved to intensify and integrate measures against NTDs, and to plan interventions to improve the health and social well-being of affected populations. Accordingly, in 2015 the main recommendation themes emerging from the 11th meeting of the Strategic and Technical Advisory Group for NTDs were:

- Aligning NTDs with UHC at country level
- Closer collaboration in UHC reform
- Monitoring equity and quality in UHC
- Strengthening laboratory support for essential national activities in NTD control, elimination and eradication

| Country                | 2008 | 2009 | 2010 | 2011 |
|------------------------|------|------|------|------|
| <b>Lebanon</b>         | 0    | 0    | 0    | 1033 |
| <b>Other countries</b> | 0    | 0    | 0    | 0    |
| <b>Total</b>           | 0    | 0    | 0    | 1033 |

| Country                | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|------------------------|------|------|------|------|------|------|------|
| <b>Lebanon</b>         | 1000 | 200  | 100  | 200  | 100  | 200  | 300  |
| <b>Other countries</b> | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| <b>Total</b>           | 1000 | 200  | 100  | 200  | 100  | 200  | 300  |

Published jointly by the Lebanese Ministry of Public Health (MoPH) and the World Health Organization (WHO). For Correspondence: Tel: +961 2 511214 Fax: +961 2 511212; E-mail: [emro@who.int](mailto:emro@who.int) or [arabic@who.int](mailto:arabic@who.int). The epidemiological data is provided by the MoPH and is not verified by WHO.

6.01

2020

[EPI Monitor Volume 7, Issue 5, May \[pdf 858kb\]](#)

[EPI Monitor Volume 7, Issue 4, April \[pdf 1.3Mb\]](#)

[EPI Monitor Volume 7, Issue 3, March \[pdf 653kb\]](#)

[EPI Monitor Volume 7, Issue 2, February \[pdf 653kb\]](#)

[EPI Monitor Volume 7, Issue 1, January \[pdf 650kb\]](#)

## **2019**

[EPI Monitor Volume 6, Issue 12, December \[pdf 650kb\]](#)

[EPI Monitor Volume 6, Issue 11, November \[pdf 784kb\]](#)

[EPI Monitor Volume 6, Issue 10, October \[pdf 791kb\]](#)

[EPI Monitor Volume 6, Issue 9, September \[pdf 712kb\]](#)

[EPI Monitor Volume 6, Issue 8, August 2019 \[pdf 335kb\]](#)

[EPI Monitor Volume 6, Issue 7, July 2019 \[pdf 770kb\]](#)

[EPI Monitor Volume 6, Issue 6, June 2019 \[pdf 902kb\]](#)

[EPI Monitor Volume 6, Issue 5, May 2019 \[pdf 343kb\]](#)

[EPI Monitor Volume 6, Issue 4, April 2019 \[pdf 660kb\]](#)

[EPI Monitor Volume 6, Issue 3, March 2019 \[pdf 834kb\]](#)[EPI Monitor Volume 6, Issue 3, March 2019 \[pdf 834kb\]](#)

[EPI Monitor Volume 6, Issue 2, February 2019 \[pdf 429kb\]](#)

[EPI Monitor Volume 6, Issue 1, January 2019 \[pdf 390kb\]](#)

## **2018**

[EPI Monitor Volume 5, Issue 11, November 2018 \[pdf 490kb\]](#)

[EPI Monitor Volume 5, Issue 10, October 2018 \[pdf 387kb\]](#)

[EPI Monitor Volume 5, Issue 9, September 2018 \[pdf 561kb\]](#)

[EPI Monitor Volume 5, Issue 8, August 2018 \[pdf 379kb\]](#)

[EPI Monitor Volume 5, Issue 7, July 2018 \[pdf 539kb\]](#)

[EPI Monitor Volume 5, Issue 6, June 2018 \[pdf 381kb\]](#)

[EPI Monitor Volume 5, Issue 5, May 2018 \[pdf 647kb\]](#)

[EPI Monitor Volume 5, Issue 4, April 2018 \[pdf 585kb\]](#)

[EPI Monitor Volume 5, Issue 3, March 2018 \[pdf 513kb\]](#)

[EPI Monitor Volume 5, Issue 2, February 2018 \[pdf 500kb\]](#)

[EPI Monitor Volume 5, Issue 1, January 2018 \[pdf 464kb\]](#)

## **2017**

[EPI Monitor Volume 4, Issue 12, December 2017 \[pdf 549kb\]](#)

[EPI Monitor Volume 4, Issue 11, November 2017 \[pdf 352kb\]](#)

[EPI Monitor Volume 4, Issue 10, October 2017 \[pdf 420kb\]](#)

[EPI Monitor Volume 4, Issue 9, September 2017 \[pdf 534kb\]](#)

[EPI Monitor Volume 4, Issue 8, August 2017 \[pdf 427kb\]](#)

[EPI Monitor Volume 4, Issue 7, July 2017 \[pdf 430kb\]](#)

[EPI Monitor Volume 4, Issue 6, June 2017 \[pdf 356kb\]](#)

[EPI Monitor Volume 4, Issue 5, May 2017 \[pdf 357kb\]](#)

[EPI Monitor Volume 4, Issue 4, April 2017 \[pdf 356kb\]](#)

[EPI Monitor Volume 4, Issue 3, March 2017 \[pdf 549kb\]](#)

[EPI Monitor Volume 4, Issue 2, February 2017 \[pdf 351kb\]](#)

[EPI Monitor Volume 4, Issue 1, January 2017 \[pdf 396kb\]](#)

**Related link**

[2016 issues&nbsp;](#)

Wednesday 1st of May 2024 11:49:51 PM